IVABRADINE DURING PREGNANCY: PHARMACOLOGICAL RATIONALE, MATERNAL CARDIOVASCULAR EFFECTS, AND HUMAN REPRODUCTIVE SAFETY: A NARRATIVE REVIEW
Keywords:
ivabradine; pregnancy; drug safety; teratogenicity; inappropriate sinus tachycardia; heart failure; postural orthostatic tachycardia syndrome; fetal outcome; pharmacovigilance; cardio-obstetrics.Abstract
Background: Ivabradine is a selective heart-rate-lowering agent that inhibits the hyperpolarization-activated cyclic nucleotide-gated pacemaker current (If) in the sinoatrial node. Because it reduces heart rate without a major direct negative inotropic effect, ivabradine has established therapeutic value in selected patients with chronic heart failure and stable coronary artery disease and has also been used off-label for inappropriate sinus tachycardia (IST), postural orthostatic tachycardia syndrome (POTS), and selected automatic atrial tachyarrhythmias. Pregnancy creates a particular therapeutic dilemma because maternal tachycardia may compromise cardiovascular function, whereas reproductive animal studies have demonstrated embryo-fetal toxicity and teratogenic effects.
Objective: To critically review the pharmacological rationale, maternal cardiovascular effects, preclinical reproductive toxicity, human pregnancy exposure data, and current clinical position of ivabradine during pregnancy.
Methods: A narrative synthesis of peer-reviewed human reports indexed in PubMed/MEDLINE was performed, supplemented by current regulatory information and cardiovascular pregnancy guidelines. Published reports of maternal ivabradine exposure were evaluated with particular attention to indication, gestational timing, dose, maternal response, fetal and neonatal outcome, and methodological limitations. The literature search was updated through September 2026.
Results: The largest human dataset is the German Embryotox observational study, which prospectively followed 38 pregnancies with ivabradine exposure. Thirty-two pregnancies resulted in live births, three in spontaneous abortions, and three in elective terminations. One infant had major congenital anomalies. Most women discontinued ivabradine after pregnancy recognition without cardiovascular deterioration, whereas five continued therapy for substantial periods of pregnancy. Additional case reports describe apparently successful treatment of severe IST-associated cardiomyopathy, incessant focal atrial tachycardia, acute cardiovascular disease, and POTS. A 2026 case documented continuous ivabradine exposure from preconception through delivery with reassuring maternal and fetal surveillance. Nevertheless, the cumulative human sample remains insufficient to exclude moderate or rare reproductive risks.
Conclusion: Available human evidence has not demonstrated a consistent pattern of ivabradine-associated congenital malformations, but it remains inadequate to establish reproductive safety. Current European guidance does not recommend ivabradine during pregnancy, and European product information lists pregnancy as a contraindication. When exposure occurs inadvertently, it should not be interpreted as evidence of inevitable fetal harm. In exceptional maternal cardiovascular conditions in which established alternatives are ineffective or poorly tolerated, individualized multidisciplinary assessment is essential.
References
1.Meah VL, Cockcroft JR, Backx K, Shave R, Stöhr EJ. Cardiac output and related haemodynamics during pregnancy: a series of meta-analyses. Heart. 2016;102(7):518–526. doi:10.1136/heartjnl-2015-308476.
2.Troiano NH. Physiologic and hemodynamic changes during pregnancy. AACN Adv Crit Care. 2018;29(3):273–283. doi:10.4037/aacnacc2018911.
3.Sharp A, Patient C, Pickett J, Belham M. Pregnancy-related inappropriate sinus tachycardia: a cohort analysis of maternal and fetal outcomes. Obstet Med. 2021;14(4):230–234. doi:10.1177/1753495X21990196.
4.Swedberg K, Komajda M, Böhm M, et al.; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–885. doi:10.1016/S0140-6736(10)61198-1.
5.Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013;15(1):116–121. doi:10.1093/europace/eus204.
6.Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2021;77(7):861–871. doi:10.1016/j.jacc.2020.12.029.
7.Riccioni G. Ivabradine: from molecular basis to clinical effectiveness. Adv Ther. 2010;27(3):160–167. doi:10.1007/s12325-010-0014-9.
8.Hoeltzenbein M, Lehmann ML, Beck E, Dathe K, Schaefer C. Ivabradine use in pregnant women—treatment indications and pregnancy outcome: an evaluation of the German Embryotox database. Eur J Clin Pharmacol. 2021;77(7):1029–1037. doi:10.1007/s00228-020-03066-w.
9.Babić Z, Gabrić ID, Pintarić H. Successful primary percutaneous coronary intervention in the first trimester of pregnancy. Catheter Cardiovasc Interv. 2011;77(4):522–525. doi:10.1002/ccd.22813.
10.Lappegård KT, Nordmo E. Ivabradine and nightmares: a previously unreported adverse reaction. Eur J Clin Pharmacol. 2011;67(12):1313–1314. doi:10.1007/s00228-011-1085-5.
11.Sağ S, Çoşkun H, Baran İ, Güllülü S, Aydınlar A. Inappropriate sinus tachycardia-induced cardiomyopathy during pregnancy and successful treatment with ivabradine. Anatol J Cardiol. 2016;16(3):212–213. doi:10.14744/AnatolJCardiol.2016.6813.
12.Tonko JB, Douglas H, Wright MJ. Ivabradine-sensitive incessant atrial tachycardia during pregnancy: a case report. Eur Heart J Case Rep. 2021;5(10):ytab367. doi:10.1093/ehjcr/ytab367.
13.Kahlon RK, Laurin JKH, Nath E, Raj SR. Successful ivabradine use throughout pregnancy for postural orthostatic tachycardia syndrome: a case report with reassuring maternal-fetal outcomes. Can J Cardiol. 2026. Online ahead of print. doi:10.1016/j.cjca.2026.04.019.
14.De Backer J, Haugaa KH, Hasselberg NE, et al.; ESC Scientific Document Group. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462–4568. doi:10.1093/eurheartj/ehaf193.
15.European Medicines Agency. Ivabradine/Procoralan: European Public Assessment Report and product information. EMA; updated 2025.
16.U.S. National Library of Medicine. DailyMed: Ivabradine prescribing information. Pregnancy and animal reproductive toxicity sections. DailyMed.
17.Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Cygankiewicz I, Wranicz JK. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013;18(4):338–344. doi:10.1177/1074248413478172.
18.Klein HH, Pich S. Cardiovascular changes during pregnancy. Herz. 2003;28(3):173–174. doi:10.1007/s00059-003-2455-2.
19.Duvekot JJ, Peeters LLH. Maternal cardiovascular hemodynamic adaptation to pregnancy. Obstet Gynecol Surv. 1994;49(12 Suppl):S1–S14. doi:10.1097/00006254-199412011-00001.
20.De Backer J, Haugaa KH. Contemporary interpretation of the 2025 ESC recommendations for cardiovascular disease and pregnancy. Eur Heart J Suppl. 2026;28(Suppl 5):v5.
